Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

Table 4 Base-case cost-effectiveness results (per patient): discounted lifetime costs, QALYs and incremental cost-effectiveness ratios of BOC/RGT vs. PR48 and BOC/PR48 vs. PR48

	PR48	BOC/RGT	BOC/PR48
Costs (2010 US$):
AV Therapy Drug Costs	29,573	47,582	69,928
EPO for treatment-related anemia	3,637	5,050	8,493
Monitoring Costs	2,110	1,796	2,380
SVR	0	0	0
F0-F3	7,538	4,786	4,461
Compensated Cirrhosis, F4	3,749	2,266	2,100
Decompensated Cirrhosis	4,223	2,677	2,505
Hepatocellular Carcinoma	5,043	3,128	2,915
Liver Transplantation	1,067	669	624
Post-Liver Transplant	1,822	1,155	1,081
Total Costs	58,761	69,110	94,488
Total QALYs	14.55	15.17	15.20
ICER		16,792/QALY	55,162/QALY

AV therapy – antiviral therapy; SVR – sustained virologic response; F0 – no fibrosis; F1 – portal fibrosis without septa; F2 – portal fibrosis with few septa; F3 – numerous septa without cirrhosis; F4 – cirrhosis; QALY – quality-adjusted life years; ICER – incremental cost-effectiveness ratios; PR48 – peginterferon-ribavirin regimen for 48 weeks; BOC/RGT – peginterferon–ribavirin for 4 weeks followed by peginterferon-ribavirin and boceprevir for 24 weeks, and those with a detectable hepatitis C virus (HCV) RNA level between weeks 8 and 24 received peginterferon–ribavirin from week 28 to week 48; BOC/PR48 –peginterferon–ribavirin for 48 weeks and boceprevir for 44 weeks.

ISSN: 1471-2334